Navigation Links
Aton Pharma Announces the Appointment of Dr. Fred Eshelman to Management Board
Date:2/25/2008

LAWRENCEVILLE, N.J., Feb. 25 /PRNewswire/ -- Aton Pharma, Inc., a global specialty pharmaceutical company, announced today that Dr. Fred Eshelman has joined the management board of Aton's parent company, Princeton Pharma Holdings LLC. Dr. Eshelman is the founder, Vice Chairman and CEO of Pharmaceutical Product Development, Inc. (Nasdaq: PPDI), an international contract research organization. Aton is a wholly owned subsidiary of Princeton Pharma Holdings LLC.

"We are delighted that Dr. Eshelman has agreed to join Princeton Pharma Holdings' management board," said Michael G. Wells, Chief Executive Officer of Aton Pharma. "He is a rare individual -- both an accomplished entrepreneur and an accomplished scientist. He built a very successful enterprise from the ground up and his knowledge of product development is exceptional. His insights are going to provide tremendous value to Aton as we implement our strategic plan."

"Aton is a very interesting specialty pharmaceutical company with their focus on medically essential therapeutics and I'm impressed with the amount of progress they have made in a relatively short period of time," stated Dr. Eshelman. "I look forward to lending my experience and helping this company reach its goals."

Dr. Eshelman's expertise will be helpful as Aton continues to execute its product life cycle management strategy and expand its research program, which includes partnerships with a variety of thought leaders, major medical institutions and research organizations.

Dr. Eshelman's career has included positions as Senior Vice President of Development and Vice President of Clinical Operations for the former Glaxo, Inc., as well as various roles in drug development with other pharmaceutical companies. He received his doctorate in pharmacy from the University of Cincinnati and his bachelor's degree in pharmacy from the University of North Carolina at Chapel Hill. He is a graduate of the Owner President Management (OPM) program at Harvard Business School.

About Aton Pharma, Inc.

Aton Pharma, Inc., headquartered in Lawrenceville, NJ, is a global specialty pharmaceutical company providing essential treatments for under-treated diseases and rare illnesses around the world. Aton's mission is to improve patient outcomes and quality of life worldwide by enhancing and expanding access and availability of medically essential therapeutics. Aton's portfolio of seven products, with sales in over 30 countries, targets rare and orphan metabolic, neurological, cardiovascular and ophthalmic diseases. For more information, see http://www.atonrx.com.

CONTACT Ed Stevens, 727-327-3396, Estevens3@tampabay.rr.com


'/>"/>
SOURCE Aton Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Strativa Pharmaceuticals, a Division of Par Pharmaceutical, Announces the Discontinuation of the Development Program for Pafuramidine
2. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
3. AstraZeneca Response to February 21, 2008 Ruling In Re: Alabama Medicaid Pharmaceutical AWP Litigation - cv2005-219 - Circuit Court of Montgomery, Alabama
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
5. Nycomed US Inc. Acquires Bradley Pharmaceuticals, Inc.
6. WuXi PharmaTech Schedules Fourth Quarter and Full Year 2007 Earnings Release on Wednesday, March 12, 2008
7. Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility
8. Cadence Pharmaceuticals Completes $49.3 Million Registered Direct Offering
9. Addrenex Pharmaceuticals Reaches Milestone with Filing of NDA for First Product, CloniBID, to Treat Hypertension
10. Vion Pharmaceuticals to Implement a One-for-Ten Reverse Stock Split
11. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... (PRWEB) , ... October 12, ... ... ) has launched Rosalind™, the first-ever genomics analysis platform specifically designed for ... complexity. Named in honor of pioneering researcher Rosalind Franklin, who made a ...
(Date:10/11/2017)... ... 2017 , ... Personal eye wash is a basic first aid supply for any work environment, ... eye do you rinse first if a dangerous substance enters both eyes? It’s one less ... with its unique dual eye piece. , “Whether its dirt and debris, or an acid ...
(Date:10/11/2017)...  VMS BioMarketing, a leading provider of patient support solutions, ... Educator (CNE) network, which will launch this week. The VMS ... care professionals to enhance the patient care experience by delivering ... health care professionals to help women who have been diagnosed ... ...
(Date:10/11/2017)... ... October 11, 2017 , ... A new study published ... frozen and fresh in vitro fertilization (IVF) transfer cycles. The multi-center ... success. , After comparing the results from the fresh and frozen transfer cohorts, ...
Breaking Biology Technology:
(Date:8/23/2017)... help is being enlisted in what,s thought to be the biggest study ... body –and are believed to affect health.  ... The Microbiome Immunity Project is the largest study to date of ... goal is to help advance scientific knowledge of the role of these ... The Microbiome ...
(Date:6/23/2017)... ITHACA, N.Y. , June 23, 2017  IBM ... in dairy research, today announced a new collaboration using ... the chances that the global milk supply is impacted ... project, Cornell University has become the newest academic institution ... Chain, a food safety initiative that includes IBM Research, ...
(Date:5/16/2017)...   Bridge Patient Portal , an enterprise ... EMR Systems , an electronic medical record solutions ... established a partnership to build an interface between ... Centricity™ products, including Centricity Practice Solution (CPS), Centricity ... new integrations will allow healthcare delivery networks using ...
Breaking Biology News(10 mins):